Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in Multiple-Drug-Refractory chronic hepatitis B virus patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3369-3374

  Lim, Young Suk ^a   Lee, Ji Young ^a   Lee, Danbi ^a   Shim, Ju Hyun ^a   Lee, Han Chu ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC PATIENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTANT;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84879012528     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00587-13     Document Type: Article

References (25)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45:529-538. (Pubitemid 44307383)
2. Schiff ER. 2006. Prevention of mortality from hepatitis B and hepatitis C. Lancet 368:896-897. (Pubitemid 44331366)
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73. (Pubitemid 43042691)
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686. (Pubitemid 43374518)
5. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. 2010. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52:886-893.
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521-1531.
7. Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW. 2009. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 50:743-751.
8. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A. 2004. Clinical outcome of HBe Agnegative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40:883-891. (Pubitemid 39288121)
9. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. 2010. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51: 422-430.
10. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. 2011. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53:763-773.
11. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray DF, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91-101. (Pubitemid 38040727)
12. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313. (Pubitemid 46374587)
13. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451. (Pubitemid 350047463)
14. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. 2010. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J. Hepatol. 53:449-454.
15. Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. 2009. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 50:1064-1071.
16. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60:247-254.
17. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80.
18. Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. 2012. Randomized trial of entecavir plus adefovir in patients with lamivudineresistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob. Agents Chemother. 56:2941-2947.
19. Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ. 2012. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. Antivir. Ther. 17:53-60.
20. Heo J, Ahn SH, Kweon YO, Kim BH, Chan HL-Y, Horban A, Wongcharatrawee S, Llamoso C, Lee KS. 2012. Entecavir+adefovir versus lamivudine+adefovir or entecavir alone in lamivudine-resistant chronic hepatitis B: 96-week data from the DEFINE study. Hepatology 56:392A.
21. Han KH, Hong SP, Choi SH, Shin SK, Cho SW, Ahn SH, Hahn JS, Kim SO. 2011. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir. Ther. 16:77-87.
22. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391. (Pubitemid 43980117)
23. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bommel F, Hansen BE, Wedemeyer H, Janssen HL. 2010. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J. Hepatol 52:493-500.
24. Qi X, Xiong S, Yang H, Miller M, Delaney WE, IV. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 12:355-362. (Pubitemid 46787980)
25. Fung S, Kwan P, Fabri MJ, Horban A, Pelemis M, Husa P, Hann HW, Flaherty JF, Massetto B, Dinh P, Corsa A, Kitrinos K, McHutchison JG, Gane E. 2012. Efficacy and safety of tenofovir DF (TDF) in chronic hepatitis B virus infected patients with documented lamivudine resistance. Hepatology 56:200A.